Welcome to the Diurnal website and allow me to introduce our company. Our mission is to develop new treatments and to deliver the best health outcomes for chronic endocrine conditions.

At the heart of everything we do at Diurnal is the patient.  Since Diurnal was incorporated, Diurnal’s approach has been the focussed goal of developing products that can address the unmet patient and clinical needs in endocrinology.  So how do we do this?

The Diurnal team has significant expertise in understanding and creating pharmaceutical products, taking these products through the clinical and regulatory process through to commercialisation.  In 2018 we successfully launched our first product for paediatric rare disease in Europe.  I am delighted to inform you that this product is now available and prescribed in many European countries with further launches to follow in 2020. 

We have now filed for market authorisation with the European Medicines Agency for our second product - for the treatment of an orphan disease in endocrinology.

Indeed, during 2019 we submitted four regulatory filings covering the globe, from Australia to Europe through to Israel and the US.  2020 promises to be a pivotal year for Diurnal as the outcomes of these filings will become known and as we build out our endocrine product pipeline so that we can we can achieve our goal of becoming one of the world’s leading specialty endocrinology companies.

I hope that you read further to understand the substantial work that we are carrying out in the field of endocrinology.

Martin Whitaker

Chief Executive Officer